Oral Semaglutide Reduces HbA_1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses.

ABSTRACT:

Introduction

The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) programme. The current post-hoc exploratory subgroup analyses evaluated outcomes by background medication and insulin regimen subgroups.

Methods

Data from patients in the PIONEER 3-5, 7 and 8 trials receiving once-daily oral semaglutide (14 mg/flexibly dosed) or a comparator (placebo, sitagliptin 100 mg or liraglutide 1.8 mg) were analysed for efficacy (glycated haemoglobin [HbA_1c] and body weight changes from baseline to planned end of treatment) and safety outcomes. Patients were grouped according to background medication (metfor

SUBMITTER: Pratley RE 

PROVIDER: S-EPMC7994454 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature